FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079677910> ?p ?o ?g. }

• W2079677910 endingPage "62" @default.
• W2079677910 startingPage "51" @default.
• W2079677910 abstract "In order to assess whether caffeine and theophylline have the same potency and efficacy to reverse the impairment of motor function caused by acute or chronic interruption of striatal dopamine transmission, a comparison of their dose-response relationship was made in the acute model of haloperidol-induced catalepsy, and the chronic model of unilateral lesion of the dopamine nigrostriatal pathway with 6-hydroxydopamine. At equimolar doses, both drugs reduced catalepsy intensity and increased its onset latency in a dose-dependent fashion, showing comparable potencies and attaining the maximal effect at similar doses. Catalepsy intensity: caffeine ED₅₀ = 24.1 μmol/kg [95% CI, 18.4-31.5]; theophylline ED₅₀ = 22.0 μmol/kg [95% CI, 17.0-28.4]. Catalepsy latency: caffeine ED₅₀ = 27.0 μmol/kg [95% CI, 21.1-34.6]; theophylline ED₅₀ = 28.8 μmol/kg [95% CI, 22.5-36.7]. In one group of hemiparkinsonian rats (n = 5), caffeine caused a dose-dependent recovery of the contralateral forepaw stepping: ED₅₀ = 2.4 μmol/kg/day [95% CI, 1.9-3.1]), reaching its maximum at the dose of 5.15 μmol/kg/day. When the treatment of these same rats was switched to 5.15 μmol/kg/day of theophylline, the stepping recovery was only 51 ± 12% of that induced by caffeine. Assessing the dose-response relationship of theophylline in another group of hemiparkinsonian rats (n = 7) revealed that it caused stepping recovery in an all-or-none fashion. Thus, the three lower doses had no effect, but at the dose of 5.15 μmol/kg/day theophylline suddenly increased the stepping to 56 ± 5% of the maximal effect observed when the treatment of these same rats was switched to an equimolar dose of caffeine. Increasing the dose of theophylline up to 15.45 μmol/kg/day caused no further stepping improvement since it was only 41 ± 6% of the maximal effect produced by caffeine at the dose of 5.15 μmol/kg/day. Given that theophylline showed less potency and efficacy than caffeine to reverse the motor impairment caused by chronic, but not acute, interruption of striatal dopaminergic transmission in rats, it is suggested that caffeine would provide more benefits than theophylline to improve the motor function in patients with Parkinson's disease." @default.
• W2079677910 created "2016-06-24" @default.
• W2079677910 creator A5018947082 @default.
• W2079677910 creator A5043820105 @default.
• W2079677910 creator A5060356439 @default.
• W2079677910 creator A5082181562 @default.
• W2079677910 date "2013-07-01" @default.
• W2079677910 modified "2023-09-25" @default.
• W2079677910 title "Caffeine has greater potency and efficacy than theophylline to reverse the motor impairment caused by chronic but not acute interruption of striatal dopaminergic transmission in rats" @default.
• W2079677910 cites W1968560756 @default.
• W2079677910 cites W1970147611 @default.
• W2079677910 cites W1977778248 @default.
• W2079677910 cites W1982686544 @default.
• W2079677910 cites W1982734210 @default.
• W2079677910 cites W1986784633 @default.
• W2079677910 cites W1991603311 @default.
• W2079677910 cites W1994246247 @default.
• W2079677910 cites W1994970739 @default.
• W2079677910 cites W2006440770 @default.
• W2079677910 cites W2006537215 @default.
• W2079677910 cites W2011736950 @default.
• W2079677910 cites W2014863293 @default.
• W2079677910 cites W2015252734 @default.
• W2079677910 cites W2015388168 @default.
• W2079677910 cites W2016475314 @default.
• W2079677910 cites W2019748153 @default.
• W2079677910 cites W2022599378 @default.
• W2079677910 cites W2037159158 @default.
• W2079677910 cites W2040108360 @default.
• W2079677910 cites W2041591122 @default.
• W2079677910 cites W2043885800 @default.
• W2079677910 cites W2047394221 @default.
• W2079677910 cites W2049816046 @default.
• W2079677910 cites W2060044902 @default.
• W2079677910 cites W2062079776 @default.
• W2079677910 cites W2070848488 @default.
• W2079677910 cites W2073684281 @default.
• W2079677910 cites W2087502967 @default.
• W2079677910 cites W2096327613 @default.
• W2079677910 cites W2106280018 @default.
• W2079677910 cites W2106307937 @default.
• W2079677910 cites W2130570136 @default.
• W2079677910 cites W2137171615 @default.
• W2079677910 cites W2142322475 @default.
• W2079677910 cites W2143794453 @default.
• W2079677910 cites W2163369915 @default.
• W2079677910 doi "https://doi.org/10.1016/j.neuropharm.2013.01.002" @default.
• W2079677910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23321687" @default.
• W2079677910 hasPublicationYear "2013" @default.
• W2079677910 type Work @default.
• W2079677910 sameAs 2079677910 @default.
• W2079677910 citedByCount "8" @default.
• W2079677910 countsByYear W20796779102014 @default.
• W2079677910 countsByYear W20796779102016 @default.
• W2079677910 countsByYear W20796779102018 @default.
• W2079677910 countsByYear W20796779102019 @default.
• W2079677910 countsByYear W20796779102020 @default.
• W2079677910 countsByYear W20796779102021 @default.
• W2079677910 countsByYear W20796779102022 @default.
• W2079677910 crossrefType "journal-article" @default.
• W2079677910 hasAuthorship W2079677910A5018947082 @default.
• W2079677910 hasAuthorship W2079677910A5043820105 @default.
• W2079677910 hasAuthorship W2079677910A5060356439 @default.
• W2079677910 hasAuthorship W2079677910A5082181562 @default.
• W2079677910 hasConcept C126322002 @default.
• W2079677910 hasConcept C134018914 @default.
• W2079677910 hasConcept C137183658 @default.
• W2079677910 hasConcept C185592680 @default.
• W2079677910 hasConcept C202751555 @default.
• W2079677910 hasConcept C2778095195 @default.
• W2079677910 hasConcept C2778500429 @default.
• W2079677910 hasConcept C2780476085 @default.
• W2079677910 hasConcept C2780948584 @default.
• W2079677910 hasConcept C42219234 @default.
• W2079677910 hasConcept C513476851 @default.
• W2079677910 hasConcept C55493867 @default.
• W2079677910 hasConcept C57992300 @default.
• W2079677910 hasConcept C71924100 @default.
• W2079677910 hasConcept C98274493 @default.
• W2079677910 hasConceptScore W2079677910C126322002 @default.
• W2079677910 hasConceptScore W2079677910C134018914 @default.
• W2079677910 hasConceptScore W2079677910C137183658 @default.
• W2079677910 hasConceptScore W2079677910C185592680 @default.
• W2079677910 hasConceptScore W2079677910C202751555 @default.
• W2079677910 hasConceptScore W2079677910C2778095195 @default.
• W2079677910 hasConceptScore W2079677910C2778500429 @default.
• W2079677910 hasConceptScore W2079677910C2780476085 @default.
• W2079677910 hasConceptScore W2079677910C2780948584 @default.
• W2079677910 hasConceptScore W2079677910C42219234 @default.
• W2079677910 hasConceptScore W2079677910C513476851 @default.
• W2079677910 hasConceptScore W2079677910C55493867 @default.
• W2079677910 hasConceptScore W2079677910C57992300 @default.
• W2079677910 hasConceptScore W2079677910C71924100 @default.
• W2079677910 hasConceptScore W2079677910C98274493 @default.
• W2079677910 hasFunder F4320326060 @default.
• W2079677910 hasLocation W20796779101 @default.
• W2079677910 hasLocation W20796779102 @default.
• W2079677910 hasOpenAccess W2079677910 @default.

• next